骨髓增生异常性肿瘤的分子监测:不要只关注这一领域,应考虑患者的血统
该评论指出骨髓增生异常性肿瘤(MDS)存在显著的种族差异,而IPSS-M预后工具主要基于欧洲队列数据,其适用性受限。评论批评IPSS-M仅纳入110例巴西患者样本,质疑其反映患者血统对预后准确性影响的充分性,呼吁开展按种族分层的基因组血统研究以验证IPSS-M并发现新预后标志物。
要点
- MDS的异质性包括显著的种族变异性,这一因素尚未被充分探索。
- IPSS-M预后工具主要依赖欧洲队列数据,限制其非欧洲人群的适用性。
- 亟需按种族分层的基因组血统研究以验证IPSS-M并识别新预后标志物。
核心结论
- 将种族多样性纳入预后模型对于确保其真正通用和包容至关重要,从而改善所有MDS患者的个性化治疗和护理。
研究设计与样本
- 本文为评论文章,针对Duployez和Preudhomme发表于《Br J Haematol》2024年205卷772-779页的综述进行评论。
主要发现
- Duployez等人的综述强调了分子标志物在MDS个性化治疗和疾病监测中的重要性,但未涉及遗传血统的影响。
- 评论批评IPSS-M仅纳入110例巴西患者样本,质疑其反映患者血统对预后准确性影响的充分性。
- 鉴于不同种族群体间突变谱和预后意义可能存在差异,亟需开展稳健的基因组血统研究。
关键数值与推荐
- IPSS-M的样本仅包含110例巴西患者,评论质疑其充分性。
- 研究应按种族背景对MDS患者进行分层,以调查突变发生率和影响,从而验证IPSS-M并可能识别新的预后标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- IPSS-M主要依赖欧洲队列数据,限制其非欧洲人群的适用性。
- IPSS-M仅纳入110例巴西患者样本,评论质疑其充分性。
- Duployez等人的综述未涉及遗传血统的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The heterogeneity of Myelodysplastic Neoplasm (MDS) extends beyond mutational diversity to include significant ethnic variability, a factor that has been underexplored. While the development of the IPSS-M prognostic tool has advanced our understanding of MDS, its reliance on data primarily from European cohorts limits its applicability to non-European populations. Duployez et al.'s review highlighted the importance of molecular markers in MDS for personalized treatment and disease monitoring yet did not address the impact of genetic ancestry. This commentary critiques the IPSS-M's limited sample of 110 Brazilian patients, questioning its adequacy in reflecting the influence of patient ancestry on prognostic accuracy. Given the potential for differing mutation profiles and prognostic implications across diverse ethnic groups, robust genomic ancestry studies are urgently needed. These studies should stratify MDS patients by ethnic background to investigate mutation incidence and impacts, thereby validating IPSS-M and potentially identifying new prognostic markers. Incorporating ethnic diversity into prognostic models is essential for ensuring they are truly universal and inclusive, thereby improving personalized treatment and care for all MDS patients. Commentary on: Duployez and Preudhomme. Monitoring molecular changes in the management of myelodysplastic syndromes. Br J Haematol 2024; 205:772-779.
引用
- Ribeiro Júnior HL. Molecular monitoring of myelodysplastic neoplasm: Don't just watch this space, consider the patient's ancestry. Br J Haematol. 2024. PMID: 39137917. doi:10.1111/bjh.19689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。